Internal Medicine, Endocrinology, Diabetes, & Metabolism · Little Rock, AR
NPI
1306936877
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
10001 Lile Dr
Little Rock, AR, 72205
Phone (501) 552-0500
Groups this clinician bills Medicare through
Medicare paid, 2024
$198K
6,562 services
Medicare patients, 2024
855
Average age 72
Drug cost, 2024
$4.5M
11,683 prescriptions
Company payments, 2025
$1,717
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nidhi Jain was code 99214 (office e&m - established), 1,729 times for 745 patients. In total Nidhi Jain billed 6,562 services in 59 codes, and Medicare paid $198K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,729 | 745 | $75.14 | $130K |
| 83036 Blood Count | Office | 852 | 496 | $9.30 | $7,920 |
| 82962 Clinical Chemistry | Office | 693 | 444 | $3.13 | $2,168 |
| 36415 Venipuncture Blood Collection | Office | 571 | 512 | $8.56 | $4,888 |
| 95251 Test - Miscellaneous | Office | 511 | 200 | $24.08 | $12K |
| 84443 Clinical Chemistry | Office | 402 | 282 | $16.40 | $6,593 |
| 84439 Clinical Chemistry | Office | 372 | 262 | $8.80 | $3,275 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 223 | 215 | $11.88 | $2,648 |
| 80061 Clinical Chemistry | Office | 193 | 158 | $13.12 | $2,532 |
| 80053 Clinical Chemistry | Office | 192 | 161 | $10.30 | $1,978 |
| 99204 Office E&M - New | Office | 129 | 129 | $99.87 | $13K |
| 82043 Clinical Chemistry | Office | 114 | 104 | $5.66 | $645 |
| 82570 Clinical Chemistry | Office | 114 | 104 | $5.08 | $579 |
| 82306 Clinical Chemistry | Office | 71 | 58 | $29.01 | $2,060 |
| 80048 Clinical Chemistry | Office | 45 | 38 | $8.29 | $373 |
By year: 2022 $174K for 4,771 services; 2023 $169K for 4,707 services; 2024 $198K for 6,562 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 852 | 496 | $9.30 | $7,920 |
| 82962 Clinical Chemistry | 693 | 444 | $3.13 | $2,168 |
| 36415 Venipuncture Blood Collection | 571 | 512 | $8.56 | $4,888 |
| 84443 Clinical Chemistry | 402 | 282 | $16.40 | $6,593 |
| 84439 Clinical Chemistry | 372 | 262 | $8.80 | $3,275 |
| 80061 Clinical Chemistry | 193 | 158 | $13.12 | $2,532 |
| 80053 Clinical Chemistry | 192 | 161 | $10.30 | $1,978 |
| 82043 Clinical Chemistry | 114 | 104 | $5.66 | $645 |
| 82570 Clinical Chemistry | 114 | 104 | $5.08 | $579 |
| 82306 Clinical Chemistry | 71 | 58 | $29.01 | $2,060 |
Medicare prescription drug claims, 2024
In 2024, the drug Nidhi Jain prescribed most often to Medicare patients was Ozempic (Semaglutide), with 1,539 prescriptions and refills. In total Nidhi Jain wrote 11,683 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 1,539 | 1,816 | 280 | $1.7M |
| Levothyroxine Sodium Generic | 1,126 | 2,373 | 275 | $9,296 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 796 | 1,475 | 210 | $111K |
| Jardiance Empagliflozin | 760 | 1,132 | 156 | $647K |
| Metformin Hcl Generic | 624 | 1,384 | 166 | $4,144 |
| Mounjaro Tirzepatide | 505 | 553 | 91 | $581K |
| Glimepiride Generic | 444 | 993 | 128 | $4,156 |
| Synthroid Levothyroxine Sodium | 300 | 567 | 62 | $21K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 264 | 494 | 77 | $119K |
| Metformin Hcl Er Metformin Hcl | 213 | 466 | 62 | $2,002 |
| Tresiba Flextouch U-100 Insulin Degludec | 206 | 404 | 57 | $134K |
| Novolog Flexpen Insulin Aspart | 201 | 431 | 72 | $35K |
| Gabapentin Generic | 198 | 380 | 54 | $2,864 |
| Pioglitazone Hcl Generic | 173 | 395 | 55 | $1,596 |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 171 | 388 | 71 | $31K |
Brand drugs: 6,916 claims; generic drugs: 4,014 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nidhi Jain $1,717 ($1,717 in general payments such as food, travel and fees) from 22 companies. The largest payer was Novo Nordisk Inc with $245.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 11 | $245 |
| CeQur Corporation | 1 | $200 |
| Medtronic, Inc. MDT | 1 | $196 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 9 | $137 |
| Abbvie Inc. ABBV | 5 | $109 |
| Tandem Diabetes Care, Inc. TNDM | 6 | $101 |
| Abbott Laboratories ABT | 5 | $99.68 |
| Corcept Therapeutics CORT | 4 | $83.69 |
| Beta Bionics, Inc. BBNX | 5 | $73.29 |
| Ascendis Pharma Endocrinology Inc ASND | 4 | $70.94 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.